Skip to main content

Table 4 Logistic regression analysis based on exposure to all types- and major-pDDIs

From: Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?

VariablesAll types-pDDIsaMajor-pDDIsb
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
OR (95% CI)p-valueOR (95% CI)p-valueOR (95% CI)p-valueOR (95% CI)p-value
Gender
 MaleReference  Reference  
 Female0.9 (0.6–1.4)0.80.9 (0.6–1.3)0.6
Age (Years)
 ≤30Reference Reference Reference Reference 
 31–603.5 (1.7–7.2)<  0.0011.9 (0.7–4.7)0.22.8 (1.3–5.7)0.0062.1 (0.8–5.7)0.1
 >603 (1.5–6)0.0021.5 (0.6–3.9)0.42.3 (1.1–4.8)0.021.7 (0.6–4.5)0.3
Drugs prescribed
 ≤5Reference Reference Reference Reference 
 6–108.3 (3.5–20)< 0.0017.3 (2.9–18.4)<  0.00123.4 (3.1–174.7)0.00226.1 (3.3–210)0.002
 >1053.9 (21–138)< 0.00143.3 (15.6–120)<  0.001132.3 (18–985)<  0.001144 (18–1177)<  0.001
Hospital stay (days)
 ≤2Reference Reference Reference Reference 
 3–41.4 (0.8–2.5)0.20.7 (0.3–1.3)0.31.8 (1–3.2)0.040.8 (0.4–1.6)0.5
 >43.1 (1.7–5.4)< 0.0010.9 (0.5–2)0.93.2 (1.9–5.5)< 0.0010.9 (0.5–1.9)0.9
Comorbidities
 Hypertension1.8 (1.2–2.8)0.0080.9 (0.5–1.7)0.91.4 (0.9–2.1)0.070.9 (0.5–1.5)0.5
 Diabetes mellitus2.6 (1.5–4.5)0.0011.8 (0.9–3.5)0.081.8 (1.2–2.8)0.0081.2 (0.7–2.1)0.5
 Stroke1.9 (1.1–3.3)0.011.5 (0.8–2.9)0.191.6 (1.1–2.5)0.031.4 (0.8–2.5)0.2
 Chronic obstructive pulmonary disease0.7 (0.4–1.5)0.40.4 (0.2–0.9)0.020.4 (0.2–0.9)0.03
 Ischemic heart disease1.9 (0.8–4.8)0.151.3 (0.5–3.6)0.62.1 (0.9–4.3)0.051.8 (0.8–4.4)0.2
 Urinary tract infection1 (0.5–2.3)0.91.4 (0.7–2.9)0.3
 Tuberculosis2.8 (0.8–9.6)0.093.7 (0.9–16.2)0.084.8 (1.6–14.4)0.0048.2 (1.9–34.7)0.004
 Hepatitis0.7 (0.3–1.7)0.50.7 (0.3–1.6)0.4
 Chronic kidney disease1.5 (0.5–4.6)0.50.7 (0.3–1.7)0.4
 Asthma2.7 (0.6–11.8)0.21.4 (0.5–4.1)0.5
  1. pDDIs Potential drug-drug interactions
  2. aHosmer–Lemeshow goodness-of-fit test: p = 0.5
  3. bHosmer–Lemeshow goodness-of-fit test: p = 0.7